A phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial: The ASSET (Abatacept Systemic SclErosis Trial) is an international, placebo-controlled, double blind trial of early diffuse cutaneous systemic sclerosis. This trial assesses abatacept (Orencia ®) in patients with early diffuse SSc with less than or equal to 36 months.

A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD): The The STRATUS Study is a trial to evaluate the safety and efficacy of abituzumab when given in combination with mycophenolate in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH): This study aims to evaluate the safety and tolerability of rituximab for the treatment of SSc-PAH, while looking at the drug’s effect on PAH. Rituximab is approved by the Food and Drug Administration (FDA) for the treatment of some cancers of the lymphatic system and for some autoimmune diseases (i.e. advanced rheumatoid arthritis).

Prospective Registry of Early Systemic Sclerosis (PRESS) Phenotypic, Serologic, and Biomarker/Genetic Characteristics of Early Diffuse Cutaneous Systemic Sclerosis: The purpose of this study is to take a closer look at scleroderma patients’ clinical, radiological, and laboratory information associated with routine medical care, and to obtain biological specimens for testing.

Interested in Participating
  • Participating in Research

    If you are interested in participating in any of our research trials, please contact:
    Afshin Zartoshti at
    Phone: 212-342-2751